TN2014000425A1 - Cyclic bridgehead ether dgat1 inhibitors - Google Patents

Cyclic bridgehead ether dgat1 inhibitors

Info

Publication number: TN2014000425A1
Authority: TN; Tunisia
Prior art keywords: bridgehead; cyclic; ether; dgat1 inhibitors; dgat1
Prior art date: 2012-04-27

Application number

TN2014000425A

Other languages

English (en)

Inventor

Xin Chen

Yiping Ding

Rohit Duvadie

Yu Gai

Tyler Harrison

Qian Liu

Jay Larrow

Justin Yik Ching Mao

Sejal Patel

Jiong Ye

Frederic Zecri

Xuchun Zheng

Rui Zheng

Yizong Zhou

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-27

Filing date

2014-10-13

Publication date

2016-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-13 Application filed by Novartis Ag filed Critical Novartis Ag

2016-03-30 Publication of TN2014000425A1 publication Critical patent/TN2014000425A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TN2014000425A 2012-04-27 2014-10-13 Cyclic bridgehead ether dgat1 inhibitors TN2014000425A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261639341P	2012-04-27	2012-04-27
US201361787695P	2013-03-15	2013-03-15
CN2013072735		2013-03-15
PCT/IB2013/053292 WO2013160873A1 (fr)	2012-04-27	2013-04-25	Inhibiteurs de dgat1 à ponts éthers cycliques

Publications (1)

Publication Number	Publication Date
TN2014000425A1 true TN2014000425A1 (en)	2016-03-30

Family

ID=48577190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2014000425A TN2014000425A1 (en)	2012-04-27	2014-10-13	Cyclic bridgehead ether dgat1 inhibitors

Country Status (26)

Country	Link
US (2)	US8993619B2 (fr)
EP (1)	EP2852590B1 (fr)
JP (1)	JP6042529B2 (fr)
KR (1)	KR20150013194A (fr)
CN (1)	CN104395309B (fr)
AP (1)	AP3592A (fr)
AR (1)	AR090859A1 (fr)
AU (1)	AU2013254307B2 (fr)
BR (1)	BR112014026760A8 (fr)
CA (1)	CA2870336A1 (fr)
CL (1)	CL2014002822A1 (fr)
CO (1)	CO7111275A2 (fr)
CR (1)	CR20140494A (fr)
EA (1)	EA025050B1 (fr)
EC (1)	ECSP14030538A (fr)
ES (1)	ES2624291T3 (fr)
IL (1)	IL235313A0 (fr)
MA (1)	MA37439B1 (fr)
MX (1)	MX357768B (fr)
PE (2)	PE20150724A1 (fr)
PH (1)	PH12014502413A1 (fr)
SG (1)	SG11201406526WA (fr)
TN (1)	TN2014000425A1 (fr)
TW (1)	TW201348239A (fr)
UY (1)	UY34767A (fr)
WO (1)	WO2013160873A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104583218B (zh)	2012-04-26	2018-04-24	百时美施贵宝公司	作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (fr)	2013-01-14	2014-07-17	Incyte Corporation	Composés de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
PT2945939T (pt)	2013-01-15	2020-06-08	Incyte Holdings Corp	Compostos tiazole e piridina carboxamidas úteis como inibidores das quinases pim
US8962660B2 (en) *	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators
US9556197B2 (en)	2013-08-23	2017-01-31	Incyte Corporation	Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (fr)	2014-07-14	2016-01-21	Incyte Corporation	Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
CN104292190B (zh) *	2014-09-03	2016-05-04	哈尔滨工业大学	一种β-溴代四氢呋喃类化合物的合成方法
CN104292189B (zh) *	2014-09-03	2016-05-04	哈尔滨工业大学	一种β-丙二酸二乙酯取代四氢呋喃类化合物的合成方法
US9540347B2 (en)	2015-05-29	2017-01-10	Incyte Corporation	Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh)	2015-09-09	2021-08-01	美商英塞特公司	Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en)	2015-10-02	2018-03-20	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN113366000A (zh) *	2018-09-18	2021-09-07	百时美施贵宝公司	作为lpa拮抗剂的氧杂双环酸

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200303742A (en)	2001-11-21	2003-09-16	Novartis Ag	Organic compounds
EP1631260A2 (fr)	2003-02-28	2006-03-08	Transform Pharmaceuticals, Inc.	Compositions pharmaceutiques a base d'un co-cristal
JP4637843B2 (ja)	2003-05-20	2011-02-23	ノバルティスアーゲー	ペルオキシソーム増殖因子活性化受容体のリガンドとしてのｎ−アシル窒素ヘテロ環
WO2006017542A1 (fr) *	2004-08-06	2006-02-16	Merck & Co., Inc.	Composés de sulfonyle comme inhibiteurs de la 11-béta-hydroxystéroide déshydrogénase-1
SG10201408806UA (en) *	2006-03-31	2015-02-27	Novartis Ag	New compounds
ES2535083T3 (es) *	2007-12-20	2015-05-05	Astrazeneca Ab	Compuestos de carbamoilo como inhibidores 190 de DGAT1
PT2781516T (pt) *	2010-10-07	2017-03-15	Novartis Ag	Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
US8962660B2 (en) *	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators

2013
- 2013-04-25 BR BR112014026760A patent/BR112014026760A8/pt not_active Application Discontinuation
- 2013-04-25 KR KR1020147032910A patent/KR20150013194A/ko not_active Ceased
- 2013-04-25 WO PCT/IB2013/053292 patent/WO2013160873A1/fr not_active Ceased
- 2013-04-25 CN CN201380034256.8A patent/CN104395309B/zh not_active Expired - Fee Related
- 2013-04-25 AU AU2013254307A patent/AU2013254307B2/en not_active Ceased
- 2013-04-25 ES ES13727385.0T patent/ES2624291T3/es active Active
- 2013-04-25 EA EA201491970A patent/EA025050B1/ru not_active IP Right Cessation
- 2013-04-25 SG SG11201406526WA patent/SG11201406526WA/en unknown
- 2013-04-25 MA MA37439A patent/MA37439B1/fr unknown
- 2013-04-25 EP EP13727385.0A patent/EP2852590B1/fr not_active Not-in-force
- 2013-04-25 PE PE2014001902A patent/PE20150724A1/es not_active Application Discontinuation
- 2013-04-25 AP AP2014008018A patent/AP3592A/xx active
- 2013-04-25 CA CA2870336A patent/CA2870336A1/fr not_active Abandoned
- 2013-04-25 MX MX2014013002A patent/MX357768B/es active IP Right Grant
- 2013-04-25 JP JP2015507656A patent/JP6042529B2/ja not_active Expired - Fee Related
- 2013-04-25 PE PE2016000359A patent/PE20160802A1/es not_active Application Discontinuation
- 2013-04-26 AR ARP130101409A patent/AR090859A1/es unknown
- 2013-04-26 US US13/871,586 patent/US8993619B2/en not_active Expired - Fee Related
- 2013-04-26 TW TW102115141A patent/TW201348239A/zh unknown
- 2013-04-26 UY UY0001034767A patent/UY34767A/es not_active Application Discontinuation
2014
- 2014-10-13 TN TN2014000425A patent/TN2014000425A1/fr unknown
- 2014-10-20 CL CL2014002822A patent/CL2014002822A1/es unknown
- 2014-10-23 IL IL235313A patent/IL235313A0/en unknown
- 2014-10-27 PH PH12014502413A patent/PH12014502413A1/en unknown
- 2014-10-27 CR CR20140494A patent/CR20140494A/es unknown
- 2014-10-27 CO CO14237492A patent/CO7111275A2/es active IP Right Grant
- 2014-11-27 EC ECIEPI201430538A patent/ECSP14030538A/es unknown
2015
- 2015-02-20 US US14/628,205 patent/US20150166563A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2015514798A (ja)	2015-05-21
CL2014002822A1 (es)	2015-04-24
UY34767A (es)	2013-11-29
SG11201406526WA (en)	2014-11-27
AU2013254307A1 (en)	2014-10-30
EA025050B1 (ru)	2016-11-30
AP2014008018A0 (en)	2014-10-31
CA2870336A1 (fr)	2013-10-31
US8993619B2 (en)	2015-03-31
BR112014026760A2 (pt)	2017-06-27
CR20140494A (es)	2015-03-13
MA37439B1 (fr)	2017-02-28
AP3592A (en)	2016-02-15
PE20160802A1 (es)	2016-09-03
ECSP14030538A (es)	2015-11-30
PE20150724A1 (es)	2015-05-17
BR112014026760A8 (pt)	2018-01-16
AU2013254307B2 (en)	2016-05-26
ES2624291T3 (es)	2017-07-13
US20150166563A1 (en)	2015-06-18
EP2852590A1 (fr)	2015-04-01
IL235313A0 (en)	2014-12-31
US20130289058A1 (en)	2013-10-31
EP2852590B1 (fr)	2017-02-01
CO7111275A2 (es)	2014-11-10
MX2014013002A (es)	2015-01-22
MA37439A1 (fr)	2016-07-29
CN104395309A (zh)	2015-03-04
AR090859A1 (es)	2014-12-10
MX357768B (es)	2018-07-24
TW201348239A (zh)	2013-12-01
EA201491970A1 (ru)	2015-03-31
PH12014502413A1 (en)	2015-01-12
WO2013160873A1 (fr)	2013-10-31
KR20150013194A (ko)	2015-02-04
CN104395309B (zh)	2016-09-28
JP6042529B2 (ja)	2016-12-14

Publication	Publication Date	Title
PH12014502413A1 (en)	2015-01-12	Cyclic bridgehead ether dgat1 inhibitors
PH12018500177A1 (en)	2018-07-30	Compositions useful for treating disorders related to kit and pdfgr
MX2015014666A (es)	2016-03-01	Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
IN2014KN02601A (fr)	2015-05-08
AU2015207757A8 (en)	2017-05-11	N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
NZ729603A (en)	2022-02-25	Heteroaryl compounds as btk inhibitors and uses thereof
TN2017000009A1 (en)	2018-07-04	Spirocycloheptanes as inhibitors of rock.
PH12016501192B1 (en)	2016-08-15	Tetrahydropyridopyrazines modulators of gpr6
GEAP201814268A (en)	2018-02-12	Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2017004618A (es)	2017-10-23	Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2016005760A (es)	2016-07-18	Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MY195743A (en)	2023-02-08	Isoxazole Hydroxamic Acid Compounds as LPXC Inhibitors
PH12017500841A1 (en)	2017-10-30	2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
IN2015DN01151A (fr)	2015-06-26
PH12018500446A1 (en)	2018-09-10	Pyridinone dicarboxamide for use as bromodomain inhibitors
SG10201900541QA (en)	2019-02-27	Derivatives of xanthone compounds
MX2016006975A (es)	2016-10-12	Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PH12016500347A1 (en)	2016-05-16	Triazolopyridine compounds, compositions and methods of use thereof
PH12015502032A1 (en)	2016-01-18	Azetidinyloxyphenylpyrrolidine compounds
MX365315B (es)	2019-05-29	Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
MX347541B (es)	2017-04-28	Analogos de acido sialico.
IN2015DN02109A (fr)	2015-08-14
SG10201803880TA (en)	2018-07-30	Stable compositions of neuroactive peptides
PH12017501147A1 (en)	2018-03-05	Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
TN2010000608A1 (en)	2012-05-24	Heteroaryl derivatives as dgat1 inhibitors